Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system

PLoS Neglected Tropical Diseases

Volumn 5, Issue 2, 2011, Pages

  Osorio, Yaneth ^a,b,d   Travi, Bruno L ^a,b,d   Renslo, Adam R ^c   Peniche, Alex G ^a,b,d   Melby, Peter C ^a,b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ACYCLIC HYDROCARBON SUBSTITUENT; ALKALOID DERIVATIVE; AMPHOTERICIN B; ANTIMYCIN A1; AROMATIC COMPOUND; BENZOPYRAN DERIVATIVE; DISULFIRAM; FLUCONAZOLE; FURAN DERIVATIVE; ISOCARBOSTYRIL DERIVATIVE; LUCIFERASE; MACROCYCLIC COMPOUND; MILTEFOSINE; MONENSIN; NORTRIPTYLINE; ORGANOLEAD COMPOUND; PENTAMIDINE; PHENANTHRIDINE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PURINE DERIVATIVE; PYRAN DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; STEROID; TERPENE DERIVATIVE; UNINDEXED DRUG; XANTHENE DERIVATIVE; ANTIPROTOZOAL AGENT;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEPG2; CHEMICAL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SCREENING; EX VIVO STUDY; EXPLANT; FEMALE; HAMSTER; HOST PARASITE INTERACTION; IN VITRO STUDY; LEISHMANIA DONOVANI; MACROPHAGE; NONHUMAN; OUTCOME ASSESSMENT; PARASITE LOAD; SPLEEN CELL; VISCERAL LEISHMANIASIS; ANIMAL; CELL LINE; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LIVER CELL; METABOLISM; METHODOLOGY; ORGAN CULTURE TECHNIQUE; PARASITOLOGY; REPORTER GENE; SPLEEN;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; CRICETINAE; DRUG EVALUATION, PRECLINICAL; FEMALE; GENES, REPORTER; HEPATOCYTES; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LUCIFERASES; ORGAN CULTURE TECHNIQUES; SPLEEN;

EID: 79952474741     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000962     Document Type: Article

References (59)

1. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
2. Handman E, Kedzierski L, Uboldi AD, Goding JW, (2008) Fishing for anti-leishmania drugs: principles and problems. Adv Exp Med Biol 625: 48-60.
3. Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D, (1999) Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 43: 278-282.
4. Valiathan R, Dubey ML, Mahajan RC, Malla N, (2006) Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate. Exp Parasitol 114: 103-108.
5. Murray HW, Granger AM, Mohanty SK, (1991) Response to chemotherapy in experimental visceral leishmaniasis: T cell- dependent but interferon-gamma- and interleukin-2-independent. J Infect Dis 163: 622-624.
6. Murray HW, Montelibano C, Peterson R, Sypek JP, (2000) Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J Infect Dis 182: 1497-1502.
7. Murray HW, Oca MJ, Granger AM, Schreiber RD, (1989) Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 83: 1253-1257.
8. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F, (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30: 2935-2943.
9. Sacks D, Anderson C, (2004) Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol Rev 201: 225-238.
10. Gifawesen C, Farrell JP, (1989) Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect Immun 57: 3091-3096.
11. Melby PC, Chandrasekar B, Zhao W, Coe JE, (2001) The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like response. J Immunol 166: 1912-1920.
12. Melby PC, Tryon VV, Chandrasekar B, Freeman GL, (1998) Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect Immun 66: 2135-2142.
13. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S, (1998) Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 177: 815-818.
14. Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, et al. (1993) In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma [see comments]. J Clin Invest 91: 1644-1648.
15. Murray HW, Teitelbaum RF, (1992) L-arginine-dependent reactive nitrogen intermediates and the antimicrobial effect of activated human mononuclear phagocytes. J Infect Dis 165: 513-517.
16. Denis M, (1994) Human monocytes/macrophages: NO or NO? J Leuk Biol 55: 682-684.
17. Perez LE, Chandrasekar B, Saldarriaga OA, Zhao W, Arteaga LT, et al. (2006) Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen. J Immunol 176: 5519-5528.
18. Sacks D, Melby P, (1998) Animal models for the analysis of immune responses to leishmaniasis. In: Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W, editors. Current Protocols in Immunology: John Wiley and Sons, Inc pp. 19.12.11-19.12.20.
19. Roy G, Dumas C, Sereno D, Wu Y, Singh AK, et al. (2000) Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 110: 195-206.
20. Corraliza IM, Campo ML, Soler G, Modolell M, (1994) Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 174: 231-235.
21. Melby PC, Yang YZ, Cheng J, Zhao W, (1998) Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 66: 18-27.
22. Lim LC, England DM, Glowacki NJ, DuChateau BK, Schell RF, (1995) Involvement of CD4+ T lymphocytes in induction of severe destructive Lyme arthritis in inbred LSH hamsters. Infect Immun 63: 4818-4825.
23. Liu H, Steiner BM, Alder JD, Baertschy DK, Schell RF, (1990) Immune T cells sorted by flow cytometry confer protection against infection with Treponema pallidum subsp. pertenue in hamsters. Infect Immun 58: 1685-1690.
24. Heemskerk J, Tobin AJ, Ravina B, (2002) From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nat Neurosci 5 (Suppl): 1027-1029.
25. Piccioni F, Roman BR, Fischbeck KH, Taylor JP, (2004) A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum Mol Genet 13: 437-446.
26. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, et al. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77.
27. Glover CJ, Hite K, DeLosh R, Scudiero DA, Fivash MJ, et al. (2003) A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay. Anal Biochem 320: 157-169.
28. Marx C, Berger C, Xu F, Amend C, Scott GK, et al. (2006) Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Dev Technol 4: 273-284.
29. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, et al. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62: 4316-4324.
30. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R, (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24: 167-175.
31. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
32. Riss TL, Moravec RA, (2004) Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev Technol 2: 51-62.
33. Duan H, Takaishi Y, Imakura Y, Jia Y, Li D, et al. (2000) Sesquiterpene alkaloids from Tripterygium hypoglaucum and Tripterygium wilfordii: a new class of potent anti-HIV agents. J Nat Prod 63: 357-361.
34. Sacks DL, Lal SL, Shrivastava SN, Blackwell J, Neva FA, (1987) An analysis of T cell responsiveness in Indian kala-azar. J Immunol 138: 908-913.
35. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, et al. (2004) The immunopathology of experimental visceral leishmaniasis. Immunol Rev 201: 239-253.
36. Lang T, Goyard S, Lebastard M, Milon G, (2005) Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol 7: 383-392.
37. Sereno D, Cordeiro da Silva A, Mathieu-Daude F, Ouaissi A, (2007) Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol Int 56: 3-7.
38. Callahan HL, Portal AC, Devereaux R, Grogl M, (1997) An axenic amastigote system for drug screening. Antimicrob Agents Chemother 41: 818-822.
39. Sereno D, Lemesre JL, (1997) Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41: 972-976.
40. Lira R, Sundar S, Makharia A, Kenney R, Gam A, et al. (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180: 564-567.
41. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ, (2008) Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 9: 1-11.
42. Scheers EM, Ekwall B, Dierickx PJ, (2001) In vitro long-term cytotoxicity testing of 27 MEIC chemicals on Hep G2 cells and comparison with acute human toxicity data. Toxicol In Vitro 15: 153-161.
43. Schoonen WG, de Roos JA, Westerink WM, Debiton E, (2005) Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol In Vitro 19: 491-503.
44. Gerets HH, Hanon E, Cornet M, Dhalluin S, Depelchin O, et al. (2009) Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. Toxicol In Vitro 23: 319-332.
45. Dambach DM, Andrews BA, Moulin F, (2005) New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol 33: 17-26.
46. Fournet A, Gantier JC, Gautheret A, Leysalles L, Munos MH, et al. (1994) The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. J Antimicrob Chemother 33: 537-544.
47. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, et al. (2001) Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 65: 685-689.
48. Koyama J, (2006) Anti-infective quinone derivatives of recent patents. Recent Pat Antiinfect Drug Discov 1: 113-125.
49. Saravia NG, Escorcia B, Osorio Y, Valderrama L, Brooks D, et al. (2006) Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Vaccine 24: 4247-4259.
50. Roberts L, Egan TJ, Joiner KA, Hoppe HC, (2008) Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum. Antimicrob Agents Chemother 52: 1840-1842.
51. Rocha LG, Almeida JR, Macedo RO, Barbosa-Filho JM, (2005) A review of natural products with antileishmanial activity. Phytomedicine 12: 514-535.
52. Zilberstein D, Dwyer DM, (1984) Antidepressants cause lethal disruption of membrane function in the human protozoan parasite Leishmania. Science 226: 977-979.
53. Burchmore RJ, Barrett MP, (2001) Life in vacuoles-nutrient acquisition by Leishmania amastigotes. Int J Parasitol 31: 1311-1320.
54. Bahamontes-Rosa N, Robin A, Ambrosio AR, Messias-Reason I, Beitz E, et al. (2008) Monoquaternary ammonium derivatives inhibit growth of protozoan parasites. Parasitol Int 57: 132-137.
55. Choubey V, Maity P, Guha M, Kumar S, Srivastava K, et al. (2007) Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism. Antimicrob Agents Chemother 51: 696-706.
56. Chan C, Yin H, Garforth J, McKie JH, Jaouhari R, et al. (1998) Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. J Med Chem 41: 148-156.
57. Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, Dias Filho BP, Morgado-Diaz JA, et al. (2005) Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 49: 176-182.
58. Lala S, Pramanick S, Mukhopadhyay S, Bandyopadhyay S, Basu MK, (2004) Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target 12: 165-175.
59. Cavalli A, Bolognesi ML, (2009) Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J Med Chem 52: 7339-7359.